Document is current

Article History

Received: 13 April 2020

Accepted: 22 April 2020

First Online: 7 May 2020

Compliance with ethical standards

:

: This study was conducted in accordance with the ethical standards of the Declaration of Helsinki. Because of the retrospective nature of this analysis and the use of de-identified patient data, informed consent was not obtained from patients for this study.

: JY, DP, and PC are employees and shareholders of Incyte Corporation. JKK and JK are employees of Cardinal Health. CM was an employee of Cardinal Health at the time of the study. MRG served as a consultant or in advisory roles for Incyte Corporation, Daiichi Sankyo, Trovagene, Ariad, Amgen, Pfizer, Cardinal Health, BMS/Celgene, Merck, Astellas, Premier, and Agios; received research funding from Incyte Corporation, Amgen, Forma Therapeutics, Janssen, Genentech, and Novartis; and has equity ownership in Medtronic. RM served in a consultancy role for Novartis and received research funding from Incyte Corporation, Genentech, CTI Biopharma, Gilead, NS Pharma, Pfizer, and Promedior. SV has received research funding from Incyte Corporation, Roche, NS Pharma, Celegene, Gilead, Promedior, CTI BioPharma, Genentech, Blueprint Medicines, Novartis, Sierra Oncology, Pharma Essentia, AstraZeneca, Ital Pharma, and Protagonist Therapeutics, and consulting fees from Constellation, Pragmatist, Sierra Oncology, Incyte Corporation, Novartis, and Celgene.